Abstract
The development of osteoporosis involves the interaction of multiple environmental and genetic factors. Through combined genetic and genomic approaches, we identified the lipoxygenase gene Alox15 as a negative regulator of peak bone mineral density in mice. Crossbreeding experiments with Alox15 knockout mice confirmed that 12/15-lipoxygenase plays a role in skeletal development. Pharmacologic inhibitors of this enzyme improved bone density and strength in two rodent models of osteoporosis. These results suggest that drugs targeting the 12/15-lipoxygenase pathway merit investigation as a therapy for osteoporosis.
Original language | English (US) |
---|---|
Pages (from-to) | 229-232 |
Number of pages | 4 |
Journal | Science |
Volume | 303 |
Issue number | 5655 |
DOIs | |
State | Published - Jan 9 2004 |
ASJC Scopus subject areas
- General